» Articles » PMID: 35482859

Stepwise-edited, Human Melanoma Models Reveal Mutations' Effect on Tumor and Microenvironment

Abstract

Establishing causal relationships between genetic alterations of human cancers and specific phenotypes of malignancy remains a challenge. We sequentially introduced mutations into healthy human melanocytes in up to five genes spanning six commonly disrupted melanoma pathways, forming nine genetically distinct cellular models of melanoma. We connected mutant melanocyte genotypes to malignant cell expression programs in vitro and in vivo, replicative immortality, malignancy, rapid tumor growth, pigmentation, metastasis, and histopathology. Mutations in malignant cells also affected tumor microenvironment composition and cell states. Our melanoma models shared genotype-associated expression programs with patient melanomas, and a deep learning model showed that these models partially recapitulated genotype-associated histopathological features as well. Thus, a progressive series of genome-edited human cancer models can causally connect genotypes carrying multiple mutations to phenotype.

Citing Articles

TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids.

Sun Y, Maggs L, Panda A, Wright S, Cicerchia A, Jenney A Cancer Immunol Res. 2025; 13(2):210-228.

PMID: 39785827 PMC: 11790382. DOI: 10.1158/2326-6066.CIR-23-1011.


The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs).

Zhang L, Deng T, Liufu Z, Liu X, Chen B, Hu Z Elife. 2024; 13.

PMID: 39688960 PMC: 11651657. DOI: 10.7554/eLife.99340.


Characterization of cancer-driving nucleotides (CDNs) across genes, cancer types, and patients.

Zhang L, Deng T, Liufu Z, Chen X, Wu S, Liu X Elife. 2024; 13.

PMID: 39688957 PMC: 11651658. DOI: 10.7554/eLife.99341.


In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy.

Bowman R, Dunbar A, Mishra T, Xiao W, Waarts M, Maestre I Cancer Cell. 2024; 42(11):1955-1969.e7.

PMID: 39532065 PMC: 11561369. DOI: 10.1016/j.ccell.2024.10.009.


Quantifying tumor specificity using Bayesian probabilistic modeling for drug and immunotherapeutic target discovery.

Li G, Schnell D, Bhattacharjee A, Yarmarkovich M, Salomonis N Cell Rep Methods. 2024; 4(11):100900.

PMID: 39515334 PMC: 11705768. DOI: 10.1016/j.crmeth.2024.100900.


References
1.
Shain A, Bastian B . From melanocytes to melanomas. Nat Rev Cancer. 2016; 16(6):345-58. DOI: 10.1038/nrc.2016.37. View

2.
Knight S, Xie L, Deng W, Guglielmi B, Witkowsky L, Bosanac L . Dynamics of CRISPR-Cas9 genome interrogation in living cells. Science. 2015; 350(6262):823-6. DOI: 10.1126/science.aac6572. View

3.
Dever D, Bak R, Reinisch A, Camarena J, Washington G, Nicolas C . CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. 2016; 539(7629):384-389. PMC: 5898607. DOI: 10.1038/nature20134. View

4.
Ciriello G, Miller M, Aksoy B, Senbabaoglu Y, Schultz N, Sander C . Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013; 45(10):1127-33. PMC: 4320046. DOI: 10.1038/ng.2762. View

5.
Jensen T, Schmidt H, Moller H, Donskov F, Hoyer M, Sjoegren P . Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer. 2011; 118(9):2476-85. DOI: 10.1002/cncr.26511. View